The Regulator
FDA rejected Summit Therapeutics’ lung cancer drug ivonescimab, saying slower tumor growth without a proven survival gain is not enough. Summit, the Miami drug developer, said November 15 that the Food and Drug Administration (FDA) issued a complete response letter, the agency’s formal notice that an application cannot be approved as submitted. The application sought approval of ivonescimab, an antibody that blocks two cancer-growth pathways at once, plus platinum chemotherapy for EGFR-mutated non-squamous non-small cell lung cancer that progressed after a prior targeted drug. In the Phase 3 HARMONi trial, progression-free survival met statistical significance, but overall survival showed only a “positive trend” that was not statistically significant. Summit says the FDA found substantial evidence of effectiveness is not established without a significant overall survival gain, and that the progression-free benefit alone does not support a positive benefit-risk profile. A later post hoc analysis put the overall survival hazard ratio at 0.76, which Summit cites but which was not the trial’s primary result. Who it hits: Summit shareholders and its partner Akeso, and any developer eyeing the first U.S. approval of this drug class, since Summit says none exists. Safety data in the release: 7.3% of ivonescimab patients stopped treatment for drug-related events versus 5.0% on chemotherapy alone. The release discloses no resubmission plan or timeline, and we did not verify the stock reaction. Confidence: Med, because the FDA letter itself is not public and this account rests on Summit’s own release. Sources: Summit Therapeutics press release.
KFF Health News reports the Pan American Health Organization has concluded the United States lost measles elimination status, with a public announcement planned for Tuesday. The November 14 report cites unnamed researchers with knowledge of the deliberations, who say PAHO, the World Health Organization’s regional office for the Americas, found measles has reestablished regular transmission here, relying on one analysis from the Centers for Disease Control and Prevention (CDC) and one from independent experts. We found no PAHO statement, so the conclusion is unconfirmed until it speaks. What is documented: CDC’s own page, updated November 13, counts 5,412 confirmed measles cases in 2026 as of November 12, across 47 jurisdictions and 43 new outbreaks, with 96% of cases outbreak-associated, versus 2,289 cases in 2025. Kindergarten measles vaccine coverage fell to 92.4% in 2025-26 from 95.2% in 2019-20. An HHS spokesperson attributes the resurgence to vaccination gaps that opened years ago and says HHS and CDC provided about $100 million in additional outbreak funding. Who it hits: state and local health departments, hospitals and schools absorbing outbreak response. KFF cites a Johns Hopkins estimate of roughly $125 million in outbreak costs. Confidence: Low on the PAHO conclusion (anonymous sourcing, no PAHO document); High on the CDC figures. Sources: CDC measles cases and outbreaks page. Supplemental: KFF Health News report.
Two Florida defendants face a 31-count federal indictment in what prosecutors call a $51 million health care fraud scheme. The Department of Health and Human Services Office of Inspector General (OIG) listed the case November 12. Charlie Bernard Griffin III, 61, of Jacksonville, is charged with health care fraud and money laundering, and Ethelbert Chinenye Nwanegbo, 47, of St. Johns, with money laundering only. The U.S. Attorney’s Office for the Middle District of Florida announced it, and each count carries up to 20 years in prison. Per the headline, Griffin is a pharmacy owner and Nwanegbo an accountant. Who it hits: whichever federal health program was billed, which OIG’s summary does not name, along with a scheme period that it also omits. The Justice Department release could not be retrieved this run. These are allegations; an indictment is not a finding of guilt. Confidence: Med on the charges and the $51 million figure as stated by OIG; Low on mechanism, which the primary summary does not give. Sources: HHS OIG enforcement listing.
Quiet note: Monday’s Federal Register carries the hospice and home health enrollment freeze extensions, the Head Start pay-rule rescission and the West Nile requests for information, all covered in Sunday’s issue, and the Federal Register’s health filings today otherwise held only routine information-collection notices.
Free. One email a day at 6pm your time, or one summary every Friday. Switch or stop anytime.